Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026)
Stereotaxis (STXS) posted quarterly Cash from Financing Activities of $4.7 million for Q1 2026, up 14637.5% year-over-year from N/an in Q1 2025, and down 32.18% quarter-over-quarter from $7.0 million in Q4 2025.
Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Cash from Financing Activities for 17 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 14637.5% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.4 million (up 6404.01% YoY), while the FY2025 annual figure was $14.8 million, up 4870.71% from the prior year.
- Cash from Financing Activities fell to $4.7 million in Q1 2026 per STXS's latest filing, from $7.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.7 million in Q3 2025 and bottomed at -$26000.0 in Q2 2023.
- Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $54000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 145.61% — and 2026, when it surged 14637.5%.
- Stereotaxis' Cash from Financing Activities stood at $61000.0 in 2022, then plunged by 57.38% to $26000.0 in 2023, then jumped by 511.54% to $159000.0 in 2024, then surged by 4273.58% to $7.0 million in 2025, then plunged by 32.18% to $4.7 million in 2026.
- Business Quant data shows STXS's Cash from Financing Activities at $4.7 million in Q1 2026, $7.0 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.72 Mn |
| Mar 31, 2026 | 4.72 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |